FdaApplication
NDA 209296
Identifiers
- fda_app_no: NDA209296
Properties
| Property | Value |
|---|---|
| applicant_name | HERON THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2017-11-09 |
Revenue by product
CINVANTI
| Period | Revenue |
|---|---|
| Q2 2026 | $21.8M |
| Q1 2026 | $20.5M |
| Q4 2025 | $22.9M |
| Q3 2025 | $24.0M |
| Q2 2025 | $24.1M |
| Q1 2025 | $25.7M |
| Q4 2024 | $26.9M |
| Q3 2024 | $22.7M |
| Q2 2024 | $24.9M |
| Q1 2024 | $25.6M |
| Q4 2023 | $24.3M |
| Q3 2023 | $23.3M |
| Q2 2023 | $24.5M |
| Q1 2023 | $22.9M |
| Q4 2022 | $23.1M |
| Q3 2022 | $21.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CINVANTI | APREPITANT | 130MG/18ML (7.2MG/ML) | EMULSION;INTRAVENOUS |
1 product